BioSpace News Archive

Peter Jones, a professor of pharmacology at the University of Nevada in Reno, has been researching the disease for years and may have helped to unlock one of the first treatments for the disease.

Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.

Amplexor and Genpact announced that they are forming a strategic alliance where Genpact will provide enhanced Digital Transformation services to support Amplexor’s Regulatory Information Management solution.

Screenings available on select Thursdays in February at MinuteClinic locations nationwide

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that the data of its clinical studies with its lead product candidate, Bria-IMT™, will be presented the at the Annual Symposium of Society of Surgical Oncology (SSO) 2020

Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct Relief and Dispensary of Hope – to stock insulin at nearly 200 U.S. free clinics through 2022.

Encompass Health Corp. and the University of Iowa Health System, the nonprofit corporation that supports the clinical, academic and research programs of University of Iowa Health Care, announced they have entered into an agreement to jointly own a 40-bed, freestanding inpatient rehabilitation hospital currently under construction in Coralville, Iowa..

Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today reported financial results for the second quarter and first six months of fiscal year 2020 ended December 31, 2019.

Ikena Oncology, a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies, today announced dosing of the first patient in the first Phase 1 clinical trial evaluating IK-175 (formerly KYN-175), an internally-developed, orally administered, selective aryl hydrocarbon receptor (AHR) antagonist, in patients with advanced solid tumors.

Century Therapeutics, a Versant Ventures-founded developer of next-generation allogeneic cell therapies, today announced the appointments of Joseph Jimenez to its board of directors and Greg Russotti, PhD, as chief technology officer.